317 related articles for article (PubMed ID: 2566679)
1. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
Kramer TH; Shook JE; Kazmierski W; Ayres EA; Wire WS; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1989 May; 249(2):544-51. PubMed ID: 2566679
[TBL] [Abstract][Full Text] [Related]
2. Opioid receptor selectivity of beta-endorphin in vitro and in vivo: mu, delta and epsilon receptors.
Shook JE; Kazmierski W; Wire WS; Lemcke PK; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1988 Sep; 246(3):1018-25. PubMed ID: 2843623
[TBL] [Abstract][Full Text] [Related]
3. Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions.
Shook JE; Pelton JT; Lemcke PK; Porreca F; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1987 Jul; 242(1):1-7. PubMed ID: 2886635
[TBL] [Abstract][Full Text] [Related]
4. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic evaluation of a cyclic somatostatin analog with antagonist activity at mu opioid receptors in vitro.
Shook JE; Pelton JT; Wire WS; Hirning LD; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1987 Mar; 240(3):772-7. PubMed ID: 2882015
[TBL] [Abstract][Full Text] [Related]
6. The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons.
Chieng B; Connor M; Christie MJ
Mol Pharmacol; 1996 Sep; 50(3):650-5. PubMed ID: 8794906
[TBL] [Abstract][Full Text] [Related]
7. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
8. [3H]-[H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2] ([3H]CTOP), a potent and highly selective peptide for mu opioid receptors in rat brain.
Hawkins KN; Knapp RJ; Lui GK; Gulya K; Kazmierski W; Wan YP; Pelton JT; Hruby VJ; Yamamura HI
J Pharmacol Exp Ther; 1989 Jan; 248(1):73-80. PubMed ID: 2563293
[TBL] [Abstract][Full Text] [Related]
9. Peptide opioid antagonist separates peripheral and central opioid antitransit effects.
Shook JE; Pelton JT; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1987 Nov; 243(2):492-500. PubMed ID: 2824748
[TBL] [Abstract][Full Text] [Related]
10. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
11. H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2: a potent and selective antagonist opioid receptors.
Gulya K; Lui GK; Pelton JT; Kazmierski W; Hruby VJ; Yamamura HI
NIDA Res Monogr; 1986; 75():209-12. PubMed ID: 2893264
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells.
Zadina JE; Harrison LM; Ge LJ; Kastin AJ; Chang SL
J Pharmacol Exp Ther; 1994 Sep; 270(3):1086-96. PubMed ID: 7932156
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors.
Kazmierski W; Wire WS; Lui GK; Knapp RJ; Shook JE; Burks TF; Yamamura HI; Hruby VJ
J Med Chem; 1988 Nov; 31(11):2170-7. PubMed ID: 2903246
[TBL] [Abstract][Full Text] [Related]
14. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors.
Pelton JT; Kazmierski W; Gulya K; Yamamura HI; Hruby VJ
J Med Chem; 1986 Nov; 29(11):2370-5. PubMed ID: 2878079
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
17. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.
Horan PJ; Wild KD; Kazmierski WM; Ferguson R; Hruby VJ; Weber SJ; Davis TP; Fang L; Knapp RJ; Yamamura HI
Eur J Pharmacol; 1993 Mar; 233(1):53-62. PubMed ID: 8386089
[TBL] [Abstract][Full Text] [Related]
18. SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors.
Williams CL; Rosenfeld GC; Dafny N; Fang SN; Hruby VJ; Bowden G; Cullinan CA; Burks TF
J Pharmacol Exp Ther; 1994 May; 269(2):750-5. PubMed ID: 8182541
[TBL] [Abstract][Full Text] [Related]
19. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine.
Abbruscato TJ; Thomas SA; Hruby VJ; Davis TP
J Pharmacol Exp Ther; 1997 Jan; 280(1):402-9. PubMed ID: 8996221
[TBL] [Abstract][Full Text] [Related]
20. Cyclic somatostatin analogues as potent antagonists at mu-, but not delta- and kappa-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the brain.
Mulder AH; Wardeh G; Hogenboom F; Kazmierski W; Hruby VJ; Schoffelmeer AN
Eur J Pharmacol; 1991 Nov; 205(1):1-6. PubMed ID: 1687463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
